Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) have been given an average broker rating score of 1.00 (Strong Buy) from the five analysts that cover the company, Zacks Investment Research reports. Five equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price target of $30.20 for the company and are anticipating that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Nightstar Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.
Several equities research analysts have recently issued reports on NITE shares. BMO Capital Markets started coverage on shares of Nightstar Therapeutics in a research report on Monday, October 23rd. They set an “outperform” rating and a $30.00 price objective on the stock. Jefferies Group started coverage on shares of Nightstar Therapeutics in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Chardan Capital started coverage on shares of Nightstar Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Leerink Swann started coverage on shares of Nightstar Therapeutics in a research report on Monday, October 23rd. They set an “outperform” rating and a $25.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $31.00 price objective (up previously from $29.00) on shares of Nightstar Therapeutics in a research report on Wednesday, January 17th.
Nightstar Therapeutics (NASDAQ:NITE) traded down $0.41 during trading on Friday, hitting $12.44. 7,700 shares of the stock traded hands, compared to its average volume of 27,434. Nightstar Therapeutics has a 52-week low of $11.99 and a 52-week high of $24.93.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/10/brokerages-anticipate-nightstar-therapeutics-plc-nite-to-post-0-19-eps.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.